Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A combined immunodeficiency in which other clinical features are present in other organ systems in addition to immunodeficiency.
No HPO annotations are available for this condition.
Activated PI3K delta syndrome (APDS) is a rare inborn error of immunity characterized primarily by frequent infections, lymphoproliferation, and autoimmune manifestations. To date, at least 250 individuals have been identified with a pathogenic variant in PIK3CD (for APDS1) or PIK3R1 (for APDS2) [, , , , ]. The following description of the phenotypic features associated with this condition is based on these reports. It is important to note that the severity and presence of these clinical findings can vary widely among affected individuals. Some may present with mild symptoms, while others experience severe manifestations that significantly impact quality of life. The variability within the spectrum of APDS highlights the importance of individualized care and management strategies. Table 2. Activated PI3K Delta Syndrome: Frequency of Select Features
No consensus clinical diagnostic criteria for activated PI3K delta syndrome (APDS) have been published.
APDS types 1 (APDS1) and 2 (APDS2) are characterized by a spectrum of clinical manifestations primarily involving the immune system, leading to increased susceptibility to infections, autoimmunity, and lymphoproliferation. APDS should be considered in probands with the following suggestive findings:
Clinical findings
Source: GeneReviews —
No approved treatments are currently available for combined immunodeficiency syndrome. The disease remains an area of unmet medical need.
No clinical practice guidelines for activated PI3K delta syndrome (APDS) have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.
To establish the extent of disease and needs in an individual diagnosed with APDS, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 8. Activated PI3K Delta Syndrome: Recommended Surveillance
1 clinical trial registered, 1 recruiting. Interventions under study include biologic therapy. Research is primarily sponsored by academic and government institutions.
93 publications have been identified in PubMed for combined immunodeficiency syndrome. Research spans Review / Meta-Analysis (27%), Basic Science / Preclinical (19%), and Clinical Trial Publication (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 21 | 27% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 2:53 PM UTC
Common questions about combined immunodeficiency syndrome
Feature | % of Persons w/Feature | Comment |
|---|---|---|
Sinopulmonary infections | 96%-100% | Severe /or recurrent |
Bronchiectasis | 18%-60% | — |
Lymphoproliferation | 71%-89% | Incl splenomegaly, hepatomegaly, lymphadenopathy |
Growth delays | 45%-62% | — |
Herpes virus infections | 36%-49% | Persistent, severe, /or recurrent |
Enteropathy | 25%-51% | Lymphoid aggregates may be seen on histology. |
Lymphoma | 12%-28% | Particularly early onset |
Autoimmune cytopenias | 19%-30% | May be refractory to conventional therapy |
Autoimmune autoinflammatory disease | 17%-42% Neurodevelopmental delay | 19%-31% |
Source: GeneReviews — "Activated PI3K Delta Syndrome"
Table 4. Genes of Interest in the Differential Diagnosis of Activated PI3K Delta Syndrome
Gene(s) | Disorder | MOI | Features of Disorder |
|---|---|---|---|
AICDA | Hyper IgM syndrome 2 (HIGM2) (OMIM 605258) | AR | Recurrent infections, hypogammaglobulinemia, IgM, lymphoid hyperplasia |
TNFRSF13C | Common variable immunodeficiency (CVID) (OMIM PS607594) | ARAD | Recurrent infections, hypogammaglobulinemia, autoimmunity, lymphoproliferation |
CD40 | Hyper IgM syndrome 3 (HIGM3) (OMIM 606843) | AR | Recurrent infections, hypogammaglobulinemia, IgM, lymphoid hyperplasia |
CD40LG | X-linked hyper IgM syndrome (HIGM1) | XL SH2D1A XIAP | — |
X-linked lymphoproliferative disease | XL | Immune dysregulation | More severe EBV infections |
UNG | Hyper IgM syndrome 5 (HIGM5) (OMIM 608106) | AR | Recurrent infections |
CTLA4 | CTLA4 haploinsufficiency (OMIM 616100) | AD | Recurrent infections, autoimmunity, lymphoproliferation |
LRBA | LRBA deficiency (OMIM 614700) | AR | — |
STAT3 | Autoimmune disease, multisystem, infantile-onset, 1 (OMIM 615952) | AD1 | T helper 17 cells phosphorylated STAT3 AD = autosomal dominant; APDS = activated PI3K delta syndrome; AR = autosomal recessive; CTLA-4 = cytotoxic T-lymphocyte protein 4; EBV = Epstein-Barr virus; MOI = mode of inheritance; STAT3 = signal transducer and activator of transcription 3; XL = X-linked 1. |
Source: GeneReviews — "Activated PI3K Delta Syndrome"
Biomarker and diagnostic research for combined immunodeficiency syndrome has been reported in the published literature.
Table 5.
Activated PI3K Delta Syndrome: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Comprehensive physical exam | To assess for presence of lymphadenopathy, splenomegaly, hepatomegaly
| • Detailed review of infection history
EBV, CMV, HSV PCR in blood relevant serologic testing
JCV PCR if patient received rituximab1
| To identify patterns indicative of immunodeficiency
| • CBC w/differential
Immunoglobulin levels (IgG, IgA, IgM, IgE)
Lymphocyte subset analysis incl nave/memory T cells B-cell subsets
Vaccine-specific antibody titers
| To evaluate immune function identify immunodeficiency
| Imaging studies (e.g., ultrasound, CT, MRI) | To detect organomegaly lymphadenopathy
B-cell clonality studies by V-beta spectratyping
LDH, EBV/CMV PCR
| To evaluate for susceptibility to lymphoproliferative disorders
| • Spirometry
Consider chest CT
| To detect underlying respiratory issues
| • Endosc...
Source: GeneReviews — "Activated PI3K Delta Syndrome"
There are currently two clinical trials evaluating the safety and efficacy of leniolisib in individuals age one to six years (NCT05693129) and four to 11 years old (NCT05438407). Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "Activated PI3K Delta Syndrome"
1 trial found
Evaluation |
|---|
Frequency |
|---|
Infections | Blood/sputum cultures | As needed for symptoms EBV/CMV/HSV PCR |
Lymphoproliferative disorders | CBC, B-cell counts, LDH | Every 6-12 months Abdominal US |
Autoimmune disorders | ANA testing, TSH, TPO | Annually |
Respiratory issues | Regular pulmonary function tests incl spirometry | Every 12 mos (to monitor lung health intervene early if issues are detected) Chest CT |
Gastrointestinal manifestations | Colonoscopy | Symptomatically as needed to identify manage gastrointestinal involvement Liver ultrasound studies |
Developmental | Psychiatric assessment | As needed ANA = antinuclear antibody; CMV = cytomegalovirus; EVB = Epstein-Barr virus; HSV= herpes simplex virus; LDH = lactate dehydrogenase; PCR = polymerase chain reaction; TSH = thyroid-stimulating hormone; TPO = thyroid peroxidase |
Source: GeneReviews — "Activated PI3K Delta Syndrome"
Laboratory research |
15 |
19% |
Clinical study results | 11 | 14% |
Disease patterns and progression | 11 | 14% |
Patient case studies | 10 | 13% |
Testing and diagnosis research | 5 | 6% |
New treatment approaches | 5 | 6% |
Other research | 1 | 1% |
Leite OHC (2026). [PMID: 41289937](https://pubmed.ncbi.nlm.nih.gov/41289937/). *Clin Biomech (Bristol)*. [Epidemiology / Natural History]
Gallego JC (2026). [PMID: 42018217](https://pubmed.ncbi.nlm.nih.gov/42018217/). *Braz J Microbiol*. [Basic Science / Preclinical]
Colín-García K (2026). [PMID: 42161110](https://pubmed.ncbi.nlm.nih.gov/42161110/). *Ecotoxicol Environ Saf*. [Diagnostic / Biomarker]
Almotiri A (2026). [PMID: 42238289](https://pubmed.ncbi.nlm.nih.gov/42238289/). *Saudi Med J*. [Review / Meta-Analysis]
Chico-Garcia JL (2026). [PMID: 42137633](https://pubmed.ncbi.nlm.nih.gov/42137633/). *Ther Adv Neurol Disord*. [Case Report / Case Series]
Yadav RM (2026). [PMID: 41949132](https://pubmed.ncbi.nlm.nih.gov/41949132/). *Indian J Med Res*. [Epidemiology / Natural History]
Miller RZ (2026). [PMID: 41451822](https://pubmed.ncbi.nlm.nih.gov/41451822/). *Curr Opin Allergy Clin Immunol*. [Review / Meta-Analysis]
Roskoski R Jr (2026). [PMID: 42107510](https://pubmed.ncbi.nlm.nih.gov/42107510/). *Pharmacol Res*. [Review / Meta-Analysis]
Kökcü Karadağ Şİ (2026). [PMID: 41708578](https://pubmed.ncbi.nlm.nih.gov/41708578/). *Scand J Immunol*. [Review / Meta-Analysis]
Roufosse F (2026). [PMID: 41242921](https://pubmed.ncbi.nlm.nih.gov/41242921/). *Eur J Intern Med*. [Other]